<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Drug fever</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Drug fever</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Drug fever</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Rekha Pai Mangalore, MBBS, FRACP, MPH, DTM&amp;H</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Denis Spelman, MBBS, FRACP, FRCPA, MPH</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Keri K Hall, MD, MS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Aug 14, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Clinicians are universally aware that medications can cause fever, although reliable data on incidence are not available. Fever can be the sole manifestation in 3 to 5 percent of adverse drug reactions [<a href="#rid1">1,2</a>]. The risk of developing drug fever increases with the number of drugs prescribed, especially in older adult patients. </p><p>The recognition of drug fever is clinically important. Failure to recognize the etiologic relationship between a drug and fever often has undesired consequences including extra testing, unnecessary therapy, and longer hospital stays.</p><p>This topic reviews the clinical approach to drug fever. The general treatment of fever, approach to fever of unknown origin, and fever in specific patient populations are discussed in detail elsewhere:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/2734.html" rel="external">"Pathophysiology and treatment of fever in adults"</a>.) </p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/2737.html" rel="external">"Fever of unknown origin in adults: Etiologies"</a> and  <a class="medical medical_review" href="/z/d/html/2736.html" rel="external">"Fever of unknown origin in adults: Evaluation and management"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/5996.html" rel="external">"Fever of unknown origin in children: Etiology"</a> and  <a class="medical medical_review" href="/z/d/html/5993.html" rel="external">"Fever of unknown origin in children: Evaluation"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/16708.html" rel="external">"Overview of neutropenic fever syndromes"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/1624.html" rel="external">"Fever in the intensive care unit"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/2886.html" rel="external">"Fever in the surgical patient"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/4453.html" rel="external">"Intrapartum fever"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/3888.html" rel="external">"Evaluation of fever in the returning traveler"</a>.)</p><p></p><p class="headingAnchor" id="H2"><span class="h1">DEFINITION</span><span class="headingEndMark"> — </span>For the purpose of this discussion, drug fever is a disorder characterized by fever that coincides with administration of a drug and disappears after the discontinuation of the drug, when no other cause for the fever is evident after a careful clinical history, physical examination, and laboratory investigation [<a href="#rid3">3</a>]. </p><p>Other definitions, such as "the febrile response to a drug without cutaneous manifestations" [<a href="#rid4">4</a>], have been used, but in our view, these are overly restrictive. Data on drug fever are largely derived from hundreds of single case reports and a few small series. There are no controlled trials on this subject, and reporting bias may significantly distort the view.</p><p class="headingAnchor" id="H3"><span class="h1">MECHANISMS</span><span class="headingEndMark"> — </span>The mechanisms of drug fever are multiple and, in many cases, poorly or incompletely understood. However, most authorities classify drug-related fevers into five broad categories [<a href="#rid1">1,2,4-6</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Hypersensitivity reactions</p><p class="bulletIndent1"><span class="glyph">●</span>Idiosyncratic reactions</p><p class="bulletIndent1"><span class="glyph">●</span>Reactions that are direct extensions of the pharmacologic action of the drug</p><p class="bulletIndent1"><span class="glyph">●</span>Altered thermoregulatory mechanisms</p><p class="bulletIndent1"><span class="glyph">●</span>Reactions that are directly related to administration of the drug</p><p></p><p class="headingAnchor" id="H1436397924"><span class="h2">Hypersensitivity</span><span class="headingEndMark"> — </span>Hypersensitivity is the most common cause of drug fever [<a href="#rid1">1-5,7</a>]. Drugs or their metabolites can interact with the human immune system and elicit any of the hypersensitivity reactions through immunoglobin mediation, formation of circulating antigen-antibody complexes, or stimulation of T- and B-cell responses [<a href="#rid8">8,9</a>]. Any one episode may involve multiple antigenic determinants and mechanisms. </p><p>Clinically important drug-induced hypersensitivity reactions occur due to immediate hypersensitivity reactions (type I, IgE-mediated reactions, such as anaphylaxis) and delayed-type reactions (type IV, T cell-mediated reactions) [<a href="#rid8">8</a>]. Various hypotheses, including the hapten hypothesis and the pharmacological-interactions (p-i) hypothesis, have been proposed to explain the underlying mechanisms of delayed-type reactions. (See  <a class="medical medical_review" href="/z/d/html/2086.html" rel="external">"Drug hypersensitivity: Classification and clinical features"</a>.) </p><p class="headingAnchor" id="H644322196"><span class="h3">Risk factors</span><span class="headingEndMark"> — </span>Genetic predispositions to drug hypersensitivity have been described. As an example, HLA-B*57:01 is associated with <a class="drug drug_general" data-topicid="8993" href="/z/d/drug information/8993.html" rel="external">abacavir</a> hypersensitivity, and testing for this genotype is recommended prior to using abacavir [<a href="#rid10">10,11</a>] (see  <a class="medical medical_review" href="/z/d/html/3779.html" rel="external">"Abacavir hypersensitivity reaction"</a> and  <a class="medical medical_review" href="/z/d/html/3703.html" rel="external">"Fever and rash in patients with HIV"</a>). Drug fever due to genetic predisposition has been described for drugs such as <a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">carbamazepine</a>, <a class="drug drug_general" data-topicid="8439" href="/z/d/drug information/8439.html" rel="external">allopurinol</a> (see <a class="local">'Allopurinol'</a> below), and <a class="drug drug_general" data-topicid="9657" href="/z/d/drug information/9657.html" rel="external">misoprostol</a>, a prostaglandin analog used for treatment of postpartum hemorrhage and termination of pregnancy [<a href="#rid8">8,9,11</a>]. However, pharmacogenetic tests for these and most other agents are not routinely available.</p><p>Viral infections, in particular HIV infection, can also increase the risk of drug hypersensitivities [<a href="#rid2">2</a>]. Other viral infections associated with an increased risk of drug hypersensitivity are cytomegalovirus, Epstein-Barr virus, and human herpesvirus 6 [<a href="#rid12">12</a>]. </p><p class="headingAnchor" id="H40988538"><span class="h3">Associations with specific agents</span><span class="headingEndMark"> — </span>Although virtually any drug is capable of causing fever via a hypersensitivity mechanism, the following drug classes warrant special mention.</p><p class="headingAnchor" id="H5"><span class="h4">Anticonvulsants</span><span class="headingEndMark"> — </span>Aromatic anticonvulsants such as <a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">carbamazepine</a> and <a class="drug drug_general" data-topicid="9769" href="/z/d/drug information/9769.html" rel="external">phenytoin</a>, <a class="drug drug_general" data-topicid="9763" href="/z/d/drug information/9763.html" rel="external">phenobarbital</a>, and <a class="drug drug_general" data-topicid="9811" href="/z/d/drug information/9811.html" rel="external">primidone</a> are important causes of drug fever [<a href="#rid13">13-17</a>]. The estimated incidence is 1 reaction per 5000 treated patients [<a href="#rid18">18</a>]. Fever usually begins five to six days after commencement of the drug and may be accompanied by an illness resembling infectious mononucleosis or even a lymphoma-like syndrome. When the drug is discontinued, resolution of fever and lymphadenopathy may be slow, taking from two to six weeks.</p><p>Anticonvulsants are also associated with the drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome. (See  <a class="medical medical_review" href="/z/d/html/16420.html" rel="external">"Drug reaction with eosinophilia and systemic symptoms (DRESS)"</a>.)</p><p class="headingAnchor" id="H6"><span class="h4">Minocycline</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9653" href="/z/d/drug information/9653.html" rel="external">Minocycline</a> is a widely used antimicrobial agent, and it is used as long-term therapy for certain indications. Various febrile reactions with minocycline have been reported; these are often accompanied by eosinophilia and may also be associated with joint, lung, liver, and skin involvement [<a href="#rid19">19-22</a>]. In most of these reports, patients were taking minocycline for many months to years before the reaction occurred; this may result in the drug being overlooked as the cause of the fever. (See <a class="local">'Timing of fever'</a> below.)</p><p class="headingAnchor" id="H7"><span class="h4">Other antimicrobial agents</span><span class="headingEndMark"> — </span>Antimicrobials, along with antipyretics, are the most common drugs to be prescribed for febrile illnesses; antimicrobial agents are also the most common cause of drug fever, accounting for approximately one-third of episodes [<a href="#rid23">23</a>]. This especially applies to beta-lactams, sulfonamides, and <a class="drug drug_general" data-topicid="9704" href="/z/d/drug information/9704.html" rel="external">nitrofurantoin</a> [<a href="#rid23">23</a>]. Patients with cystic fibrosis have a disproportionately high incidence of antibiotic-associated drug fever, in particular with <a class="drug drug_general" data-topicid="9775" href="/z/d/drug information/9775.html" rel="external">piperacillin</a> and imipenem-cilastatin [<a href="#rid24">24</a>].</p><p>Drug fever due to an antimicrobial agent can cause clinical confusion; recurrence of fever in a patient who has defervesced on antimicrobial treatment for an infection may be misinterpreted as relapse of the original infection. </p><p class="headingAnchor" id="H8"><span class="h4">Allopurinol</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8439" href="/z/d/drug information/8439.html" rel="external">Allopurinol</a> hypersensitivity is a rare but severe life-threatening complication of long-term allopurinol use. An allopurinol reaction should be considered in the differential diagnosis of fever in patients taking this drug. Reactions to allopurinol are associated with various severe cutaneous reactions that range from allopurinol hypersensitivity syndrome, DRESS, to Stevens-Johnson syndrome/toxic epidermal necrolysis. Fever is present with all these manifestations [<a href="#rid25">25</a>]. These reactions have been observed to occur up to eight to nine weeks (median of three weeks) after commencing allopurinol [<a href="#rid26">26</a>]. (See  <a class="medical medical_review" href="/z/d/html/1672.html" rel="external">"Pharmacologic urate-lowering therapy and treatment of tophi in patients with gout", section on 'Adverse effects'</a>.)</p><p><a class="drug drug_general" data-topicid="8439" href="/z/d/drug information/8439.html" rel="external">Allopurinol</a> should be avoided in individuals with the HLA-B*58:01 genotype, which increases the risk of allopurinol drug reaction; this association has been observed in certain East Asian ethnic groups [<a href="#rid26">26,27</a>]. Other risk factors for allopurinol reaction include high doses, drug accumulation, renal impairment, and/or concurrent use of diuretics [<a href="#rid25">25,27</a>].</p><p class="headingAnchor" id="H9"><span class="h4">Heparin</span><span class="headingEndMark"> — </span>Heparins, including low-molecular-weight heparins, are a rare cause of drug fever [<a href="#rid28">28,29</a>]. Heparin-induced fever can be particularly difficult to diagnose in critically ill or postoperative patients who often receive the drug for prophylaxis against thromboembolism.</p><p class="headingAnchor" id="H1902019749"><span class="h4">Immune checkpoint inhibitors</span><span class="headingEndMark"> — </span>Immune checkpoint inhibitors, such as <a class="drug drug_general" data-topicid="96957" href="/z/d/drug information/96957.html" rel="external">pembrolizumab</a> and <a class="drug drug_general" data-topicid="98764" href="/z/d/drug information/98764.html" rel="external">nivolumab</a>, and anti-CTLA-4 antibodies, such as <a class="drug drug_general" data-topicid="16084" href="/z/d/drug information/16084.html" rel="external">ipilimumab</a>, are antibodies that target the programmed cell death receptor 1 (PD-1)/programmed cell death-ligand 1 (PDL-1) pathway and are used for treatment of certain cancers [<a href="#rid30">30</a>]. These antibodies produce a range of immune-mediated (T cell) responses that not only have antitumor effects but can also result in a range of adverse events, including fever, pneumonitis, rash, and fatigue [<a href="#rid31">31</a>]. These are discussed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/96368.html" rel="external">"Toxicities associated with immune checkpoint inhibitors"</a>.)</p><p class="headingAnchor" id="H1726950792"><span class="h2">Fever due to an idiosyncratic reaction</span><span class="headingEndMark"> — </span>Idiosyncratic febrile drug reactions are a heterogeneous category of drug-induced fevers. These reactions include unpredictable syndromes and genetic disorders, and there is some overlap with hypersensitivity phenomena. </p><p class="headingAnchor" id="H733441132"><span class="h3">Malignant hyperthermia</span><span class="headingEndMark"> — </span>Malignant hyperthermia is a rare but dramatic event characterized by the sudden appearance of fever over 40°C, muscle rigidity, metabolic acidosis, and hemodynamic instability during general anesthesia [<a href="#rid32">32,33</a>]. Most episodes of malignant hyperthermia have been triggered by muscle-depolarizing agents, such as <a class="drug drug_general" data-topicid="9952" href="/z/d/drug information/9952.html" rel="external">succinylcholine</a>, and inhaled anesthetic agents, such as halothane. It is usually observed with the third exposure to the provoking agent but can occur with the initial exposure [<a href="#rid34">34</a>]. It is critical to recognize this syndrome because early intervention and treatment may be lifesaving. (See  <a class="medical medical_review" href="/z/d/html/401.html" rel="external">"Malignant hyperthermia: Diagnosis and management of acute crisis"</a>.)</p><p>Predisposition to malignant hyperthermia is inherited as an autosomal-dominant trait in 50 percent of cases and can affect any ethnic group. It is more common in men than women and most common in children under the age of 15 years. The primary defect is a mutation in the gene for the skeletal muscle ryanodine receptor (RyR1), which is a calcium channel found in the sarcoplasmic reticulum. (See  <a class="medical medical_review" href="/z/d/html/403.html" rel="external">"Susceptibility to malignant hyperthermia: Evaluation and management"</a>.)</p><p class="headingAnchor" id="H3759156067"><span class="h3">Neuroleptic malignant syndrome</span><span class="headingEndMark"> — </span>The neuroleptic malignant syndrome (NMS) is characterized by high fever, muscle rigidity, altered and fluctuating mental state, and dysautonomias [<a href="#rid33">33,35,36</a>]. Hyperthermia results from increased myocyte metabolic activity and altered hypothalamic thermoregulation. (See  <a class="medical medical_review" href="/z/d/html/4829.html" rel="external">"Neuroleptic malignant syndrome"</a>.)</p><p>More than 25 different drugs have been incriminated, most prominently the major tranquilizers, such as <a class="drug drug_general" data-topicid="8516" href="/z/d/drug information/8516.html" rel="external">haloperidol</a>; all of the implicated drugs are central nervous system dopamine-depleting agents. The probability of developing NMS is directly related to the antidopaminergic potency and dose of the neuroleptic agent [<a href="#rid34">34</a>].</p><p>Abrupt withdrawal of dopaminergic agents, such as <a class="drug drug_general" data-topicid="8994" href="/z/d/drug information/8994.html" rel="external">carbidopa-levodopa</a>, and <a class="drug drug_general" data-topicid="9384" href="/z/d/drug information/9384.html" rel="external">dopamine</a> agonists, such as <a class="drug drug_general" data-topicid="8508" href="/z/d/drug information/8508.html" rel="external">amantadine</a>, <a class="drug drug_general" data-topicid="9164" href="/z/d/drug information/9164.html" rel="external">bromocriptine</a>, <a class="drug drug_general" data-topicid="10246" href="/z/d/drug information/10246.html" rel="external">ropinirole</a>, and <a class="drug drug_general" data-topicid="9560" href="/z/d/drug information/9560.html" rel="external">pramipexole</a>, can also precipitate NMS. This type of NMS is called Parkinsonism-hyperpyrexia syndrome. Reintroduction of these medications leads to resolution of this syndrome [<a href="#rid37">37</a>].</p><p>NMS is associated with significant mortality unless it is recognized and the drug withdrawn. Treatment of NMS is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/4829.html" rel="external">"Neuroleptic malignant syndrome", section on 'Treatment'</a>.)</p><p class="headingAnchor" id="H1279000998"><span class="h3">Serotonin syndrome</span><span class="headingEndMark"> — </span>Serotonin syndrome is a predictable consequence of excess agonist activity of serotonin on central and peripheral 5-HT1A and 5-HT2A receptors [<a href="#rid38">38</a>]. Features include agitation, confusion, hyperthermia, and autonomic hyperactivity such as diaphoresis, tachycardia, and neuromuscular disturbances, including rigidity, clonus, and tremors. It may be precipitated by selective serotonin reuptake inhibitor (SSRI) use alone or in combination with other drugs, including L-tryptophan, lysergic acid diethylamide (LSD), <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">lithium</a>, L-dopa, <a class="drug drug_general" data-topicid="8893" href="/z/d/drug information/8893.html" rel="external">dextromethorphan</a>, <a class="drug drug_general" data-topicid="10010" href="/z/d/drug information/10010.html" rel="external">tramadol</a>, <a class="drug drug_general" data-topicid="9608" href="/z/d/drug information/9608.html" rel="external">meperidine</a>, and the monoamine oxidase inhibitors. (See  <a class="medical medical_review" href="/z/d/html/301.html" rel="external">"Serotonin syndrome (serotonin toxicity)"</a>.)</p><p class="headingAnchor" id="H2240665926"><span class="h3">Hemolysis secondary to glucose-6-phosphate deficiency</span><span class="headingEndMark"> — </span>Fever may occur in patients with glucose-6-phosphate deficiency when drugs such as <a class="drug drug_general" data-topicid="9810" href="/z/d/drug information/9810.html" rel="external">primaquine</a>, <a class="drug drug_general" data-topicid="9847" href="/z/d/drug information/9847.html" rel="external">quinine</a> sulfate, <a class="drug drug_general" data-topicid="9704" href="/z/d/drug information/9704.html" rel="external">nitrofurantoin</a>, or sulfonamides result in hemolysis and release of endogenous pyrogens [<a href="#rid34">34</a>]. Fever is a minor complication compared with the hemolytic anemia induced by these drugs. (See  <a class="medical medical_review" href="/z/d/html/7111.html" rel="external">"Diagnosis and management of glucose-6-phosphate dehydrogenase (G6PD) deficiency"</a>.)</p><p class="headingAnchor" id="H1219940343"><span class="h2">Fever as an extension of the pharmacologic effect of a drug</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Chemotherapy </strong>– The most common example of fever as an extension of the pharmacologic effect of the drug is the fever observed following cancer chemotherapy [<a href="#rid39">39</a>]. Cell necrosis and lysis release various pyrogenic substances from damaged cells; the resulting inflammatory response is also accompanied by cytokine activation of the febrile response. Fever most commonly commences three to four days after chemotherapy [<a href="#rid39">39</a>] and may last for one week or more. This early febrile response usually can be distinguished from febrile neutropenia, which rarely develops before the second week after chemotherapy.</p><p></p><p class="bulletIndent1">Drug fever can occur when BRAF inhibitors and BRAF/MEK inhibitor combinations are used for treatment of metastatic melanoma. Most notably, the combination of <a class="drug drug_general" data-topicid="89686" href="/z/d/drug information/89686.html" rel="external">dabrafenib</a> and <a class="drug drug_general" data-topicid="89685" href="/z/d/drug information/89685.html" rel="external">trametinib</a> causes fever in 40 to 60 percent of people; the mechanism is uncertain [<a href="#rid40">40</a>]. (See  <a class="medical medical_review" href="/z/d/html/15408.html" rel="external">"Systemic treatment of metastatic melanoma with BRAF and other molecular alterations"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Jarisch-Herxheimer reaction</strong> <strong>with antimicrobial therapy</strong> – The parallel situation with antimicrobial therapy is the Jarisch-Herxheimer reaction. Fever and transient exacerbation of constitutional symptoms are thought to result from the sudden release of bacterial products from injured and/or killed bacteria [<a href="#rid41">41</a>]. Classically, this reaction was described following treatment for secondary and tertiary syphilis, brucellosis, and enteric fever. It can also occur with treatment of schistosomiasis and trypanosomiasis. (See  <a class="medical medical_review" href="/z/d/html/7597.html" rel="external">"Syphilis: Treatment and monitoring", section on 'Jarisch-Herxheimer reaction'</a>.)</p><p></p><p class="bulletIndent1">Severe reactions of this type have been observed following treatment of borreliosis, particularly <em>Borrelia recurrentis</em>, with a mortality rate of approximately 5 percent. (See  <a class="medical medical_review" href="/z/d/html/7897.html" rel="external">"Clinical features, diagnosis, and management of relapsing fever", section on 'Jarisch-Herxheimer reactions'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9289" href="/z/d/drug information/9289.html" rel="external">Clozapine</a> – Patients on clozapine can develop fever due to its effects on immune modulation, which lead to increased interleukin-6 and tumor necrosis factor concentrations [<a href="#rid34">34,42</a>]. The fever is usually self-limited, and there are reports of the drug being reintroduced at a lower dose at a later date [<a href="#rid43">43</a>].</p><p></p><p class="headingAnchor" id="H10"><span class="h2">Fever due to altered thermoregulation</span><span class="headingEndMark"> — </span>The thermoregulatory center of the hypothalamus sets and maintains the core body temperature at around 37°C [<a href="#rid25">25</a>]. The physiologic mechanism of thermoregulation occurs via heat loss or heat conservation by the interaction between the hypothalamus and various parts of the central and peripheral nervous system (limbic system, brain stem, spinal cord, sympathetic ganglia) with input from peripheral and central temperature-sensing receptors. Fever occurs when host cells produce "endogenous pyrogens," including the cytokines interleukin (IL)-1 alpha and -1 beta, tumor necrosis factor (TNF)-alpha and -beta, and interferon alpha [<a href="#rid44">44</a>]. These lead to elevations in cyclo-oxygenases and local prostaglandin E2 levels, which mediate thermo-conservation through increased muscle activity (shivering), increased basal metabolic rate, and vasoconstriction.</p><p>Drugs that alter or modify one or all of the above mechanisms can cause fever. Specific examples include:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Exogenous thyroid hormone</strong> – Thyroid hormone can increase the metabolic rate and directly increase heat production. This exogenous effect can occur without regard to the underlying thyroid function [<a href="#rid6">6</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Drugs with anticholinergic activity</strong> – Such drugs, including tricyclic antidepressants, <a class="drug drug_general" data-topicid="8983" href="/z/d/drug information/8983.html" rel="external">atropine</a>, antihistamines, phenothiazines, and butyrophenone tranquilizers, can cause fever by disturbing central hypothalamic function and the peripheral effector mechanisms detailed above. Marked hyperthermia can ensue when these drugs are taken in combination [<a href="#rid2">2,4,5</a>]. Oligohydrosis and hyperthermia have also been reported with the antiseizure medication <a class="drug drug_general" data-topicid="9862" href="/z/d/drug information/9862.html" rel="external">zonisamide</a> [<a href="#rid45">45</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Sympathomimetic agents</strong> – Drugs such as amphetamines and cocaine cause peripheral vasoconstriction as a result of disturbances in central hypothalamic function and peripheral effector mechanisms. In addition, drug-induced psychomotor agitation may lead to increased muscle activity and secondary heat production [<a href="#rid38">38</a>]. As an example, 3,4-methylene dioxymethamphetamine (MDMA or "ecstasy") has sympathomimetic properties that can cause a potentially fatal acute syndrome characterized by hyperthermia, seizures, rhabdomyolysis, acute renal failure, and coagulopathy, especially when taken prior to vigorous exercise, such as dancing. This reaction is due to serotonin release and shares clinical features of serotonin syndrome [<a href="#rid46">46,47</a>]. (See  <a class="medical medical_review" href="/z/d/html/302.html" rel="external">"MDMA (ecstasy) intoxication", section on 'Clinical features'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Drugs that uncouple oxidative phosphorylation</strong> – Toxic concentrations of salicylates and the wood preservative pentachlorophenol can short circuit the normal oxidative phosphorylation process in mitochondria and result in excess heat production and hyperthermia. Hyperthermia in patients with salicylate toxicity is a late and serious finding requiring aggressive treatment such as hemodialysis [<a href="#rid38">38</a>]. (See  <a class="medical medical_review" href="/z/d/html/329.html" rel="external">"Salicylate (aspirin) poisoning: Clinical manifestations and evaluation"</a>.)</p><p></p><p class="headingAnchor" id="H11"><span class="h2">Fever associated with drug administration</span><span class="headingEndMark"> — </span>The parenteral administration of certain drugs can directly lead to fever. </p><p class="bulletIndent1"><span class="glyph">●</span>Solutions containing drugs and intravenous fluids can become contaminated with endotoxin or other exogenous pyrogens [<a href="#rid23">23</a>]. Such pyrogen reactions have been associated with reusable infusion sets [<a href="#rid23">23,48</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Fever can also accompany a chemical phlebitis caused by drug administration (eg, as with cephalothin or <a class="drug drug_general" data-topicid="9795" href="/z/d/drug information/9795.html" rel="external">potassium chloride</a>), and local inflammation and/or sterile abscesses can occur at sites of injection [<a href="#rid49">49</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Some drugs, such as amphotericin B and <a class="drug drug_general" data-topicid="9160" href="/z/d/drug information/9160.html" rel="external">bleomycin</a>, have intrinsic but poorly understood pyrogenic properties (see  <a class="medical medical_review" href="/z/d/html/476.html" rel="external">"Pharmacology of amphotericin B"</a>). Fever sometimes follows injections with <a class="drug drug_general" data-topicid="83875" href="/z/d/drug information/83875.html" rel="external">paraldehyde</a> and <a class="drug drug_general" data-topicid="9753" href="/z/d/drug information/9753.html" rel="external">pentazocine</a> [<a href="#rid48">48</a>].</p><p></p><p>In the past, fever sometimes resulted from drug impurities; this was a particular problem with the older formulations of <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">vancomycin</a> and <a class="drug drug_general" data-topicid="8489" href="/z/d/drug information/8489.html" rel="external">gentamicin</a> [<a href="#rid25">25,50</a>].</p><p class="headingAnchor" id="H3369625752"><span class="h1">DIAGNOSTIC EVALUATION</span></p><p class="headingAnchor" id="H1833408927"><span class="h2">Evaluate for other causes of fever</span><span class="headingEndMark"> — </span>Drug fever is generally a diagnosis of exclusion. The differential diagnosis is broad and includes all other causes of fever, such as infection, malignancy, autoimmune or autoinflammatory conditions, stroke, endocrine disorders, and conditions associated with substance use (eg, alcohol withdrawal). The approach to evaluation of fever varies by underlying patient characteristics (immunocompetent versus immunocompromised, critically ill versus outpatient, specific exposures or underlying medical conditions). In some cases, the possibility of drug fever is assessed as part of an evaluation for fever of unknown origin. Details on the general approach to fever in different patient populations are found elsewhere: </p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/2736.html" rel="external">"Fever of unknown origin in adults: Evaluation and management"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/5993.html" rel="external">"Fever of unknown origin in children: Evaluation"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/16708.html" rel="external">"Overview of neutropenic fever syndromes"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/1624.html" rel="external">"Fever in the intensive care unit"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/2886.html" rel="external">"Fever in the surgical patient"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/4453.html" rel="external">"Intrapartum fever"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/3888.html" rel="external">"Evaluation of fever in the returning traveler"</a>.)</p><p></p><p class="headingAnchor" id="H3940003413"><span class="h2">Assess for likelihood of drug fever</span><span class="headingEndMark"> — </span>In hospitalized patients, drug fever can lead to prolonged hospitalization and extensive, expensive evaluation. As an example, in a large study, each episode of drug fever prolonged hospital stay by a mean of 8.7 days and was associated with average of 5 blood cultures and 2.85 radiologic studies [<a href="#rid23">23</a>]. A detailed review of the history, presenting features, and laboratory findings may reveal potential clues to the possibility of drug fever, and thus spare repeat evaluation for other potential causes of fever. </p><p class="headingAnchor" id="H3416273148"><span class="h3">Medication history</span><span class="headingEndMark"> — </span>All of the patient’s current medications as well as their doses and durations of use should be detailed. These include over-the-counter medications, herbal medications, supplements, and recreational substances. </p><p>Although any medication can be associated with fever, review of the medication list should focus on agents or drug classes that are more frequently implicated. These include:</p><p class="bulletIndent1"><span class="glyph">●</span>Anticonvulsants (see <a class="local">'Anticonvulsants'</a> above)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Antibiotics (especially <a class="drug drug_general" data-topicid="9653" href="/z/d/drug information/9653.html" rel="external">minocycline</a>, beta-lactams, sulfonamides, <a class="drug drug_general" data-topicid="9704" href="/z/d/drug information/9704.html" rel="external">nitrofurantoin</a>) (see <a class="local">'Minocycline'</a> above and <a class="local">'Other antimicrobial agents'</a> above)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8439" href="/z/d/drug information/8439.html" rel="external">Allopurinol</a> (see <a class="local">'Allopurinol'</a> above)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Cancer therapy, including chemotherapy and immunotherapy (see <a class="local">'Fever as an extension of the pharmacologic effect of a drug'</a> above and <a class="local">'Immune checkpoint inhibitors'</a> above)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Thyroid hormone (see <a class="local">'Fever due to altered thermoregulation'</a> above)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Agents with anticholinergic effect (see <a class="local">'Fever due to altered thermoregulation'</a> above)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Sympathomimetic agents (eg, amphetamines, cocaine) (see <a class="local">'Fever due to altered thermoregulation'</a> above)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Neuroleptics (including <a class="drug drug_general" data-topicid="9289" href="/z/d/drug information/9289.html" rel="external">clozapine</a>) (see <a class="local">'Fever as an extension of the pharmacologic effect of a drug'</a> above and <a class="local">'Neuroleptic malignant syndrome'</a> above)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Selective serotonin reuptake inhibitors (SSRIs) (see <a class="local">'Serotonin syndrome'</a> above)</p><p></p><p>A previous history of drug fever, particularly with a medication related to one the patient is currently taking, should increase suspicion for drug fever. </p><p class="headingAnchor" id="H622818696"><span class="h3">Timing of fever</span><span class="headingEndMark"> — </span>The time to onset of drug fever can vary from a few hours to a few months following initiation of the offending agent. While most cases occur within the first few weeks of drug initiation, clinicians should be aware that even medications that the patient has been using chronically can be potential causes of drug fever. </p><p>The median reported time to onset of drug fever is about eight days after starting the medication [<a href="#rid23">23</a>]. However, typical time to onset varies widely by drug  (<a class="graphic graphic_table graphicRef131419" href="/z/d/graphic/131419.html" rel="external">table 1</a>) [<a href="#rid6">6,23,25,39,51-67</a>]. Additionally, most estimated times are informed by limited data from isolated case reports or series.</p><p class="headingAnchor" id="H3310418956"><span class="h3">Pattern of fever</span><span class="headingEndMark"> — </span>The fever pattern and severity of temperature rise in cases of drug fever are variable. Some features may raise the possibility of drug fever, but they are not specific to it.</p><p class="bulletIndent1"><span class="glyph">●</span>Hectic fever (ie, continuous but fluctuating fever that is characterized by wide swings that do not return to baseline temperature) is the most common fever pattern observed; however, continuous, intermittent (spiking temperatures returning to normal in between), and remitting (spiking temperatures that do not return to normal in between) fevers can also occur [<a href="#rid3">3,39</a>]. The degree of pyrexia can vary from low grade to high grade and generally has no bearing on prognosis [<a href="#rid4">4,39</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Relative bradycardia, in which the pulse rate does not rise as expected with the temperature, is seen in about 10 percent of cases and can occasionally be a useful clue to the presence of drug fever [<a href="#rid3">3</a>].</p><p></p><p class="headingAnchor" id="H232986741"><span class="h3">Associated clinical features</span><span class="headingEndMark"> — </span>Certain clinical features should raise suspicion of drug fever: </p><p class="bulletIndent1"><span class="glyph">●</span><strong>General appearance</strong> – Drug fever should be suspected in a patient who appears and feels well and is unaware of fever. However, this presentation is not specific to drug fever, and patients with drug fever can also be ill-appearing, particularly if they have serious systemic complications. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Rash </strong>– Rash or other cutaneous manifestations of hypersensitivity have been reported in up to 30 percent of patients with drug fever [<a href="#rid6">6</a>]. However, the absence of rash should not deter the clinician from pursuing the diagnosis of drug fever. In one review of 148 episodes of drug fever, rash occurred in only 18 percent of cases [<a href="#rid3">3</a>]. </p><p></p><p class="bulletIndent1">The type of rash varies and includes erythema, morbilliform eruptions, urticaria/hives, as well as severe cutaneous reactions such as nonfollicular pustules, rash with lymphadenopathy, and mucosal involvement with epidermal detachment. Fever is an important prodromal symptom of severe cutaneous reactions [<a href="#rid68">68,69</a>]. (See  <a class="medical medical_review" href="/z/d/html/15761.html" rel="external">"Acute generalized exanthematous pustulosis (AGEP)"</a> and  <a class="medical medical_review" href="/z/d/html/16420.html" rel="external">"Drug reaction with eosinophilia and systemic symptoms (DRESS)"</a> and  <a class="medical medical_review" href="/z/d/html/2091.html" rel="external">"Stevens-Johnson syndrome and toxic epidermal necrolysis: Pathogenesis, clinical manifestations, and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Neurologic, neuromuscular, and autonomic abnormalities</strong> – Muscle rigidity, dysautonomia, agitation, and confusion are clues to the presence of an idiosyncratic reaction, such as neuroleptic malignant syndrome or serotonin syndrome. (See <a class="local">'Fever due to an idiosyncratic reaction'</a> above.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Underlying conditions associated with drug fever</strong> – Drug fever occurs more frequently in certain patient populations, such as people with HIV or cystic fibrosis. Other comorbidities, such as psychiatric illnesses, active malignancy, gout, liver, and renal impairment, are associated with treatment with medications that are commonly implicated in drug fever. </p><p></p><p class="headingAnchor" id="H3704576089"><span class="h3">Suggestive laboratory abnormalities</span></p><p class="bulletIndent1"><span class="glyph">●</span>The white blood cell count can be elevated with accompanying eosinophilia in drug fever, but these findings occur in fewer than 20 percent of cases [<a href="#rid3">3</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Neutropenia or agranulocytosis can uncommonly occur in the context of drug fever, including fever associated with antimicrobial agents (eg, penicillin or cephalosporin) [<a href="#rid70">70</a>]. (See  <a class="medical medical_review" href="/z/d/html/8374.html" rel="external">"Drug-induced neutropenia and agranulocytosis", section on 'Drug-induced neutropenia'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Unexplained disturbance of liver function can also be a manifestation of a drug reaction. (See  <a class="medical medical_review" href="/z/d/html/3571.html" rel="external">"Drug-induced liver injury"</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If urine microscopy reveals pyuria, a stain for eosinophils can be performed. Eosinophiluria could suggest interstitial nephritis, and in turn, drug fever. (See  <a class="medical medical_review" href="/z/d/html/7234.html" rel="external">"Clinical manifestations and diagnosis of acute interstitial nephritis"</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Elevated creatinine kinase and myoglobinuria can suggest neuroleptic malignant syndrome. (See <a class="local">'Neuroleptic malignant syndrome'</a> above.)</p><p></p><p>Inflammatory markers, including C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR), are not particularly useful as they are nonspecific and can be normal or increased in drug fever. </p><p class="headingAnchor" id="H3606435360"><span class="h2">Establishing the diagnosis</span></p><p class="headingAnchor" id="H3797699014"><span class="h3">Drug cessation</span><span class="headingEndMark"> — </span>Stopping the offending agent can both establish a presumptive diagnosis of drug fever and treat it. In most cases, this is the only way to establish the diagnosis. In most but not all cases, resolution of drug fever will occur within 72 to 96 hours of discontinuing the offending drug.</p><p>The usual approach is to discontinue the most probable offending drug first. Identifying the most probable offending agent entails reviewing the medication history for drugs that are more frequently associated with drug fever and synthesizing other information, including timing of drug initiation relative to fever onset  (<a class="graphic graphic_table graphicRef131419" href="/z/d/graphic/131419.html" rel="external">table 1</a>), associated clinical features, whether the patient has received the drug before, and suggestive laboratory abnormalities, as discussed above. (See <a class="local">'Assess for likelihood of drug fever'</a> above.) </p><p>After cessation of that drug, if the fever subsides within a few half-lives, it is reasonable to presume that medication is the cause of the fever. If not, we proceed with sequential cessation of other drugs. The first drug can be restarted, if necessary and drugs from alternate classes are not appropriate. </p><p>Discontinuing all medications at once may eliminate the fever but may also put the patient at some risk from the underlying disease and prevent identification of the causative drug. </p><p>In cases of suspected antimicrobial-induced drug fever when ongoing antimicrobial therapy is warranted, alternate agents from a different class of antimicrobials should be used. However, there is insufficient evidence to determine whether there is cross-reactivity for drug fever amongst medications within the same antimicrobial class. </p><p class="headingAnchor" id="H26"><span class="h3">Rechallenge to confirm or exonerate a putative offending agent</span><span class="headingEndMark"> — </span>If the diagnosis of fever due to a particular agent is uncertain and it is important to confirm or reject the diagnosis (eg, because use of that agent is preferred over alternatives or it may be needed in the future), cautious rechallenge may be able to clarify the diagnosis. Rechallenge should only be performed when the following conditions are met: </p><p class="bulletIndent1"><span class="glyph">●</span>It is a planned, prospective experiment in a controlled environment where the patient can be monitored frequently for symptoms, changes in vital signs, and, in some cases, laboratory parameters [<a href="#rid71">71</a>]. This may be in a hospital or outpatient (eg, allergy consultation), depending on the presumed reaction. The duration of monitoring depends on the initial reaction and how long after initial dosing the fever occurred. If the fever was thought to be secondary to a hypersensitivity reaction, the procedure for rechallenge is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/2079.html" rel="external">"An approach to the patient with drug allergy", section on 'Graded challenge and drug provocation'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The original drug reaction was not associated with organ damage or other severe signs and symptoms, such as blistering skin reactions or reactions that involve mucous membranes [<a href="#rid72">72,73</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>There are no specific contraindications to rechallenge, such as HLA-B*57:01 genotype with <a class="drug drug_general" data-topicid="8993" href="/z/d/drug information/8993.html" rel="external">abacavir</a>, HLA-B*58:01 genotype with <a class="drug drug_general" data-topicid="8439" href="/z/d/drug information/8439.html" rel="external">allopurinol</a>, and known G6PD deficiency with hemolysis-inducing medications. (See  <a class="medical medical_review" href="/z/d/html/3779.html" rel="external">"Abacavir hypersensitivity reaction"</a> and <a class="local">'Allopurinol'</a> above and <a class="local">'Hemolysis secondary to glucose-6-phosphate deficiency'</a> above.) </p><p></p><p>If fever recurs with rechallenge of the agent, the diagnosis of drug fever and the offending agent are confirmed. If so, the drug is generally avoided.</p><p>In one study, rechallenge with the putative offending agent was undertaken in 63 of 167 cases of drug fever [<a href="#rid74">74</a>]. Fever recurred in all cases, at a median of two days, and outcomes were favorable after drug discontinuation in 97 percent of patients undergoing rechallenge. </p><p class="headingAnchor" id="H2599124"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definition</strong> – Drug fever is a disorder characterized by fever that coincides with administration of a drug and disappears after the discontinuation of the drug, when no other cause for the fever is evident after a careful clinical history, physical examination, and laboratory investigation. (See <a class="local">'Definition'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mechanisms</strong> – Although the mechanisms of drug fever are incompletely understood, they can be classified into five broad categories (see <a class="local">'Mechanisms'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Hypersensitivity – This is the most common cause of drug fever; in some cases, fever is a feature of a severe cutaneous reaction. Drugs commonly associated with fever because of hypersensitivity include anticonvulsants, antimicrobials, and <a class="drug drug_general" data-topicid="8439" href="/z/d/drug information/8439.html" rel="external">allopurinol</a>. (See <a class="local">'Hypersensitivity'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Idiosyncratic reactions – This is a heterogeneous category and includes malignant hyperthermia, neuroleptic malignant syndrome, and serotonin syndrome. (See <a class="local">'Fever due to an idiosyncratic reaction'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Direct result of the pharmacologic action of the drug – The most common example is fever following chemotherapy, which results in cell damage and release of pyrogenic substances. (See <a class="local">'Fever as an extension of the pharmacologic effect of a drug'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Altered thermoregulation – Drugs such as thyroid hormone, anticholinergic agents, and sympathomimetic agents can modify thermoregulation pathways to result in fever. (See <a class="local">'Fever due to altered thermoregulation'</a> above.) </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Reactions directly related to administration of the drug – These include contamination of parenteral fluids with endotoxin or other exogenous pyrogens, phlebitis, and intrinsic pyrogenic properties of some injectable agents, such as amphotericin or <a class="drug drug_general" data-topicid="9160" href="/z/d/drug information/9160.html" rel="external">bleomycin</a>. (See <a class="local">'Fever associated with drug administration'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Evaluation</strong> – Drug fever is a diagnosis of exclusion. After ruling out other serious causes of fever, a detailed review of the history, presenting features, and laboratory findings may reveal potential clues to the possibility of drug fever. (See <a class="local">'Diagnostic evaluation'</a> above.) </p><p></p><p class="bulletIndent1">A detailed medical history should include all current medications, including over-the-counter medications, herbal medications, supplements, and recreational substances, with a focus on drugs or drug classes that are more frequently associated with fever (eg, anticonvulsants, antibiotics, <a class="drug drug_general" data-topicid="8439" href="/z/d/drug information/8439.html" rel="external">allopurinol</a>, cancer therapy, thyroid hormone, anticholinergic or sympathomimetic agents, neuroleptics, and serotonin reuptake inhibitors).</p><p></p><p class="bulletIndent1">The median time to onset of drug fever is about eight days after initiation of the offending agent but can range from a few hours to a few months  (<a class="graphic graphic_table graphicRef131419" href="/z/d/graphic/131419.html" rel="external">table 1</a>). Even chronic medications can be potential causes of drug fever.</p><p></p><p class="bulletIndent1">Fever and rash should raise suspicion for a hypersensitivity reaction, including a serious cutaneous reaction. Fever with confusion, muscle rigidity, and/or dysautonomia should raise suspicion for a severe idiosyncratic reaction. (See <a class="local">'Associated clinical features'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Drug cessation</strong> – Stopping the offending agent can both establish a presumptive diagnosis of drug fever and treat it. The usual approach is to sequentially discontinue drugs, beginning with the most probable offending agent. Resolution of drug fever usually occurs within 72 to 96 hours of discontinuing the culprit drug. (See <a class="local">'Drug cessation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Rechallenge</strong> – If the diagnosis of fever due to a particular agent is uncertain and use of that agent rather than alternatives is preferred, cautious rechallenge may be able to clarify the diagnosis. Rechallenge should only be performed in a planned, controlled environment if the original drug reaction was not severe. (See <a class="local">'Rechallenge to confirm or exonerate a putative offending agent'</a> above.)</p><p></p><p class="headingAnchor" id="H2547318737"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Malcolm McDonald, PhD, FRACP, FRCPA, who contributed to an earlier version of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Roush MK, Nelson KM. Understanding drug-induced febrile reactions. Am Pharm 1993; NS33:39.</a></li><li><a class="nounderline abstract_t">Tabor PA. Drug-induced fever. Drug Intell Clin Pharm 1986; 20:413.</a></li><li><a class="nounderline abstract_t">Mackowiak PA, LeMaistre CF. Drug fever: a critical appraisal of conventional concepts. An analysis of 51 episodes in two Dallas hospitals and 97 episodes reported in the English literature. Ann Intern Med 1987; 106:728.</a></li><li><a class="nounderline abstract_t">Johnson DH, Cunha BA. Drug fever. Infect Dis Clin North Am 1996; 10:85.</a></li><li><a class="nounderline abstract_t">Hanson MA. Drug fever. Remember to consider it in diagnosis. Postgrad Med 1991; 89:167.</a></li><li><a class="nounderline abstract_t">Patel RA, Gallagher JC. Drug fever. Pharmacotherapy 2010; 30:57.</a></li><li><a class="nounderline abstract_t">Bayard PJ, Berger TG, Jacobson MA. Drug hypersensitivity reactions and human immunodeficiency virus disease. J Acquir Immune Defic Syndr 1992; 5:1237.</a></li><li><a class="nounderline abstract_t">Meng X, Ariza A, Waddington J, et al. Immunological Mechanisms of Drug Hypersensitivity. Curr Pharm Des 2016; 22:6734.</a></li><li><a class="nounderline abstract_t">Warrington R, Silviu-Dan F, Wong T. Drug allergy. Allergy Asthma Clin Immunol 2018; 14:60.</a></li><li><a class="nounderline abstract_t">Hughes DA, Vilar FJ, Ward CC, et al. Cost-effectiveness analysis of HLA B*5701 genotyping in preventing abacavir hypersensitivity. Pharmacogenetics 2004; 14:335.</a></li><li><a class="nounderline abstract_t">Alfirevic A, Durocher J, Elati A, et al. Misoprostol-induced fever and genetic polymorphisms in drug transporters SLCO1B1 and ABCC4 in women of Latin American and European ancestry. Pharmacogenomics 2015; 16:919.</a></li><li><a class="nounderline abstract_t">Shiohara T, Kano Y. A complex interaction between drug allergy and viral infection. Clin Rev Allergy Immunol 2007; 33:124.</a></li><li><a class="nounderline abstract_t">Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 26-1996. A seven-year-old boy with fever, lymphadenopathy, hepatosplenomegaly, and prominent eosinophilia. N Engl J Med 1996; 335:577.</a></li><li><a class="nounderline abstract_t">De Vriese AS, Philippe J, Van Renterghem DM, et al. Carbamazepine hypersensitivity syndrome: report of 4 cases and review of the literature. Medicine (Baltimore) 1995; 74:144.</a></li><li><a class="nounderline abstract_t">Vittorio CC, Muglia JJ. Anticonvulsant hypersensitivity syndrome. Arch Intern Med 1995; 155:2285.</a></li><li><a class="nounderline abstract_t">Gebauer K, Holgate C, Navaratnam A. Toxic pustuloderma. A drug induced pustulating glandular fever-like syndrome. Australas J Dermatol 1990; 31:89.</a></li><li><a class="nounderline abstract_t">Hosoda N, Sunaoshi W, Shirai H, et al. Anticarbamazepine antibody induced by carbamazepine in a patient with severe serum sickness. Arch Dis Child 1991; 66:722.</a></li><li><a class="nounderline abstract_t">Roujeau JC, Stern RS. Severe adverse cutaneous reactions to drugs. N Engl J Med 1994; 331:1272.</a></li><li><a class="nounderline abstract_t">Elkayam O, Yaron M, Caspi D. Minocycline induced arthritis associated with fever, livedo reticularis, and pANCA. Ann Rheum Dis 1996; 55:769.</a></li><li><a class="nounderline abstract_t">MacNeil M, Haase DA, Tremaine R, Marrie TJ. Fever, lymphadenopathy, eosinophilia, lymphocytosis, hepatitis, and dermatitis: a severe adverse reaction to minocycline. J Am Acad Dermatol 1997; 36:347.</a></li><li><a class="nounderline abstract_t">Gorard DA. Late-onset drug fever associated with minocycline. Postgrad Med J 1990; 66:404.</a></li><li><a class="nounderline abstract_t">Sitbon O, Bidel N, Dussopt C, et al. Minocycline pneumonitis and eosinophilia. A report on eight patients. Arch Intern Med 1994; 154:1633.</a></li><li><a class="nounderline abstract_t">Mackowiak PA. Drug fever: mechanisms, maxims and misconceptions. Am J Med Sci 1987; 294:275.</a></li><li><a class="nounderline abstract_t">Pleasants RA, Walker TR, Samuelson WM. Allergic reactions to parenteral beta-lactam antibiotics in patients with cystic fibrosis. Chest 1994; 106:1124.</a></li><li><a class="nounderline abstract_t">Stamp LK, Barclay ML. How to prevent allopurinol hypersensitivity reactions? Rheumatology (Oxford) 2018; 57:i35.</a></li><li><a class="nounderline abstract_t">Ramasamy SN, Korb-Wells CS, Kannangara DR, et al. Allopurinol hypersensitivity: a systematic review of all published cases, 1950-2012. Drug Saf 2013; 36:953.</a></li><li><a class="nounderline abstract_t">Arellano F, Sacristán JA. Allopurinol hypersensitivity syndrome: a review. Ann Pharmacother 1993; 27:337.</a></li><li><a class="nounderline abstract_t">Forni AL, Murray HW. Drug fever induced by heparin. Am J Med 1992; 92:107.</a></li><li><a class="nounderline abstract_t">Ng QX, Seng C, Ho CYX, Yeo WS. Enoxaparin: A cause of postoperative fever? Med Hypotheses 2018; 121:47.</a></li><li><a class="nounderline abstract_t">Shivaji UN, Jeffery L, Gui X, et al. Immune checkpoint inhibitor-associated gastrointestinal and hepatic adverse events and their management. Therap Adv Gastroenterol 2019; 12:1756284819884196.</a></li><li><a class="nounderline abstract_t">Naidoo J, Page DB, Li BT, et al. Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. Ann Oncol 2016; 27:1362.</a></li><li><a class="nounderline abstract_t">Nimmo SM, Kennedy BW, Tullett WM, et al. Drug-induced hyperthermia. Anaesthesia 1993; 48:892.</a></li><li><a class="nounderline abstract_t">Heiman-Patterson TD. Neuroleptic malignant syndrome and malignant hyperthermia. Important issues for the medical consultant. Med Clin North Am 1993; 77:477.</a></li><li class="breakAll">Tisdale JE, Miller DA. Drug-Induced Diseases, 3rd ed, American Society of Health-System Pharmacists, 2018.</li><li><a class="nounderline abstract_t">Caroff SN, Mann SC. Neuroleptic malignant syndrome. Med Clin North Am 1993; 77:185.</a></li><li><a class="nounderline abstract_t">Bristow MF, Kohen D. Neuroleptic malignant syndrome. Br J Hosp Med 1996; 55:517.</a></li><li><a class="nounderline abstract_t">Hocker S, Kenney DL, Ramar K. Parkinsonism-hyperpyrexia syndrome: Broadening our differential diagnosis in the ICU. Neurol Clin Pract 2013; 3:535.</a></li><li><a class="nounderline abstract_t">Eyer F, Zilker T. Bench-to-bedside review: mechanisms and management of hyperthermia due to toxicity. Crit Care 2007; 11:236.</a></li><li><a class="nounderline abstract_t">Ogawara D, Fukuda M, Ueno S, et al. Drug fever after cancer chemotherapy is most commonly observed on posttreatment days 3 and 4. Support Care Cancer 2016; 24:615.</a></li><li><a class="nounderline abstract_t">Menzies AM, Ashworth MT, Swann S, et al. Characteristics of pyrexia in BRAFV600E/K metastatic melanoma patients treated with combined dabrafenib and trametinib in a phase I/II clinical trial. Ann Oncol 2015; 26:415.</a></li><li><a class="nounderline abstract_t">Beutler B, Munford RS. Tumor necrosis factor and the Jarisch-Herxheimer reaction. N Engl J Med 1996; 335:347.</a></li><li><a class="nounderline abstract_t">Hung YP, Wang CS, Yen CN, et al. Role of cytokine changes in clozapine-induced fever: A cohort prospective study. Psychiatry Clin Neurosci 2017; 71:395.</a></li><li><a class="nounderline abstract_t">Bruno V, Valiente-Gómez A, Alcoverro O. Clozapine and Fever: A Case of Continued Therapy With Clozapine. Clin Neuropharmacol 2015; 38:151.</a></li><li><a class="nounderline abstract_t">Saper CB, Breder CD. The neurologic basis of fever. N Engl J Med 1994; 330:1880.</a></li><li><a class="nounderline abstract_t">Knudsen JF, Thambi LR, Kapcala LP, Racoosin JA. Oligohydrosis and fever in pediatric patients treated with zonisamide. Pediatr Neurol 2003; 28:184.</a></li><li><a class="nounderline abstract_t">Dar KJ, McBrien ME. MDMA induced hyperthermia: report of a fatality and review of current therapy. Intensive Care Med 1996; 22:995.</a></li><li><a class="nounderline abstract_t">Mills EM, Rusyniak DE, Sprague JE. The role of the sympathetic nervous system and uncoupling proteins in the thermogenesis induced by 3,4-methylenedioxymethamphetamine. J Mol Med (Berl) 2004; 82:787.</a></li><li><a class="nounderline abstract_t">Feng QZ, Ma XJ. Pyrogen reaction and conversion of sustained ventricular tachycardia to sinus rhythm: two case reports. Cases J 2009; 2:6637.</a></li><li><a class="nounderline abstract_t">Cuddy ML. The effects of drugs on thermoregulation. AACN Clin Issues 2004; 15:238.</a></li><li><a class="nounderline abstract_t">Cunha BA. Vancomycin. Med Clin North Am 1995; 79:817.</a></li><li><a class="nounderline abstract_t">Suresh R, Gupta S, Sathananthan R. Sulphasalazine induced three-week syndrome. J Clin Rheumatol 2009; 15:311.</a></li><li><a class="nounderline abstract_t">Ghannam M, Mansour S, Nabulsi A, Abdoh Q. Anticonvulsant hypersensitivity syndrome after phenytoin administration in an adolescent patient: a case report and review of literature. Clin Mol Allergy 2017; 15:14.</a></li><li><a class="nounderline abstract_t">Kumar KL, Reuler JB. Drug fever. West J Med 1986; 144:753.</a></li><li><a class="nounderline abstract_t">Davis RS, Stoler BS. Febrile reactions to INH. N Engl J Med 1977; 297:337.</a></li><li><a class="nounderline abstract_t">Jacobs NF Jr, Thompson SE 3rd. Spiking fever from isoniazid simulating a septic process. JAMA 1977; 238:1759.</a></li><li><a class="nounderline abstract_t">Dasta JF, Prior JA, Kurzrok S. Isoniazid-induced fever. Chest 1979; 75:196.</a></li><li><a class="nounderline abstract_t">Stewart CR, Vengrow MI, Riley TL. Double quotidian fever caused by carbamazepine. N Engl J Med 1980; 302:1262.</a></li><li><a class="nounderline abstract_t">Sheridan WP, King RW, Gerstman M. Fever as an adverse reaction to carbamazepine. Aust N Z J Med 1982; 12:520.</a></li><li><a class="nounderline abstract_t">Savran SV, Flamm MD Jr. Letter: fever as a toxic reaction to quinidine. N Engl J Med 1975; 292:427.</a></li><li><a class="nounderline abstract_t">Schlutz M, Zinneman HH, Hall WH. Drug fever caused by quinine and quinidine. Minn Med 1973; 56:668.</a></li><li><a class="nounderline abstract_t">Abrams J. Quinidine fever: an unusual manifestation of quinidine allergy. Chest 1973; 64:120.</a></li><li><a class="nounderline abstract_t">Glontz GE, Saslaw S. Methyldopa fever. Arch Intern Med 1968; 122:445.</a></li><li><a class="nounderline abstract_t">Grim SA, Romanelli F, Jennings PR, Ofotokun I. Late-onset drug fever associated with minocycline: case report and review of the literature. Pharmacotherapy 2003; 23:1659.</a></li><li><a class="nounderline abstract_t">Khoury T, Ollech JE, Chen S, et al. Azathioprine-induced fever in autoimmune hepatitis. World J Gastroenterol 2013; 19:4083.</a></li><li><a class="nounderline abstract_t">Jeurissen ME, Boerbooms AM, van de Putte LB, Kruijsen MW. Azathioprine induced fever, chills, rash, and hepatotoxicity in rheumatoid arthritis. Ann Rheum Dis 1990; 49:25.</a></li><li><a class="nounderline abstract_t">van der Klooster JM, Sucec PM, Stiegelis WF, Hagenbeek A. Fever caused by hydroxyurea: a report of three cases and review of the literature. Neth J Med 1997; 51:114.</a></li><li><a class="nounderline abstract_t">Starmans-Kool MJ, Fickers MM, Pannebakker MA. An unwanted side effect of hydroxyurea in a patient with idiopathic myelofibrosis. Ann Hematol 1995; 70:279.</a></li><li><a class="nounderline abstract_t">Feldmeyer L, Heidemeyer K, Yawalkar N. Acute Generalized Exanthematous Pustulosis: Pathogenesis, Genetic Background, Clinical Variants and Therapy. Int J Mol Sci 2016; 17.</a></li><li><a class="nounderline abstract_t">Jeung YJ, Lee JY, Oh MJ, et al. Comparison of the causes and clinical features of drug rash with eosinophilia and systemic symptoms and stevens-johnson syndrome. Allergy Asthma Immunol Res 2010; 2:123.</a></li><li><a class="nounderline abstract_t">Olaison L, Belin L, Hogevik H, Alestig K. Incidence of beta-lactam-induced delayed hypersensitivity and neutropenia during treatment of infective endocarditis. Arch Intern Med 1999; 159:607.</a></li><li><a class="nounderline abstract_t">Gans MD, Tejera DS, Jerschow E. Evaluating drug fever to beta-lactam antibiotics. Ann Allergy Asthma Immunol 2020; 124:401.</a></li><li><a class="nounderline abstract_t">Meyboom R. Intentional rechallenge and the clinical management of drug-related problems. Drug Saf 2013; 36:163.</a></li><li><a class="nounderline abstract_t">Zhang C, Van DN, Hieu C, Craig T. Drug-induced severe cutaneous adverse reactions: Determine the cause and prevention. Ann Allergy Asthma Immunol 2019; 123:483.</a></li><li><a class="nounderline abstract_t">Vodovar D, LeBeller C, Mégarbane B, et al. Drug Fever: a descriptive cohort study from the French national pharmacovigilance database. Drug Saf 2012; 35:759.</a></li></ol></div><div id="topicVersionRevision">Topic 2738 Version 29.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8237783" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Understanding drug-induced febrile reactions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3522163" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Drug-induced fever.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3565971" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Drug fever: a critical appraisal of conventional concepts. An analysis of 51 episodes in two Dallas hospitals and 97 episodes reported in the English literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8698996" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Drug fever.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2008396" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Drug fever. Remember to consider it in diagnosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20030474" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Drug fever.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1453334" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Drug hypersensitivity reactions and human immunodeficiency virus disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27697025" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Immunological Mechanisms of Drug Hypersensitivity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30275849" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Drug allergy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15247625" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Cost-effectiveness analysis of HLA B*5701 genotyping in preventing abacavir hypersensitivity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26122863" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Misoprostol-induced fever and genetic polymorphisms in drug transporters SLCO1B1 and ABCC4 in women of Latin American and European ancestry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18094951" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : A complex interaction between drug allergy and viral infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8684410" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 26-1996. A seven-year-old boy with fever, lymphadenopathy, hepatosplenomegaly, and prominent eosinophilia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7760721" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Carbamazepine hypersensitivity syndrome: report of 4 cases and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7487252" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Anticonvulsant hypersensitivity syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2151365" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Toxic pustuloderma. A drug induced pustulating glandular fever-like syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2053795" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Anticarbamazepine antibody induced by carbamazepine in a patient with severe serum sickness.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7794310" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Severe adverse cutaneous reactions to drugs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8984944" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Minocycline induced arthritis associated with fever, livedo reticularis, and pANCA.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9039216" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Fever, lymphadenopathy, eosinophilia, lymphocytosis, hepatitis, and dermatitis: a severe adverse reaction to minocycline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2371195" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Late-onset drug fever associated with minocycline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8031212" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Minocycline pneumonitis and eosinophilia. A report on eight patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3310641" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Drug fever: mechanisms, maxims and misconceptions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7924483" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Allergic reactions to parenteral beta-lactam antibiotics in patients with cystic fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29272508" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : How to prevent allopurinol hypersensitivity reactions?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23873481" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Allopurinol hypersensitivity: a systematic review of all published cases, 1950-2012.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8453174" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Allopurinol hypersensitivity syndrome: a review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1731499" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Drug fever induced by heparin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30396488" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Enoxaparin: A cause of postoperative fever?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31723355" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Immune checkpoint inhibitor-associated gastrointestinal and hepatic adverse events and their management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27072927" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7902026" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Drug-induced hyperthermia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8095087" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Neuroleptic malignant syndrome and malignant hyperthermia. Important issues for the medical consultant.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8095087" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Neuroleptic malignant syndrome and malignant hyperthermia. Important issues for the medical consultant.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8093494" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Neuroleptic malignant syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8732227" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Neuroleptic malignant syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30107018" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Parkinsonism-hyperpyrexia syndrome: Broadening our differential diagnosis in the ICU.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18096088" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Bench-to-bedside review: mechanisms and management of hyperthermia due to toxicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26108172" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Drug fever after cancer chemotherapy is most commonly observed on posttreatment days 3 and 4.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25411413" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Characteristics of pyrexia in BRAFV600E/K metastatic melanoma patients treated with combined dabrafenib and trametinib in a phase I/II clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8663859" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Tumor necrosis factor and the Jarisch-Herxheimer reaction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28106314" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Role of cytokine changes in clozapine-induced fever: A cohort prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26166236" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Clozapine and Fever: A Case of Continued Therapy With Clozapine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7832832" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : The neurologic basis of fever.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12770670" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Oligohydrosis and fever in pediatric patients treated with zonisamide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8905441" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : MDMA induced hyperthermia: report of a fatality and review of current therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15602689" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : The role of the sympathetic nervous system and uncoupling proteins in the thermogenesis induced by 3,4-methylenedioxymethamphetamine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20181168" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Pyrogen reaction and conversion of sustained ventricular tachycardia to sinus rhythm: two case reports.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15461041" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : The effects of drugs on thermoregulation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7791425" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Vancomycin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19734741" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Sulphasalazine induced three-week syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28638280" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Anticonvulsant hypersensitivity syndrome after phenytoin administration in an adolescent patient: a case report and review of literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3487884" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Drug fever.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/876321" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Febrile reactions to INH.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/578277" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Spiking fever from isoniazid simulating a septic process.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/421557" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Isoniazid-induced fever.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7366686" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Double quotidian fever caused by carbamazepine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6960873" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Fever as an adverse reaction to carbamazepine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1110732" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Letter: fever as a toxic reaction to quinidine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4733543" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Drug fever caused by quinine and quinidine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4717447" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Quinidine fever: an unusual manifestation of quinidine allergy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5687931" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Methyldopa fever.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14695046" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Late-onset drug fever associated with minocycline: case report and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23840156" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Azathioprine-induced fever in autoimmune hepatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2138007" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Azathioprine induced fever, chills, rash, and hepatotoxicity in rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9360412" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Fever caused by hydroxyurea: a report of three cases and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7599291" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : An unwanted side effect of hydroxyurea in a patient with idiopathic myelofibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27472323" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Acute Generalized Exanthematous Pustulosis: Pathogenesis, Genetic Background, Clinical Variants and Therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20358026" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Comparison of the causes and clinical features of drug rash with eosinophilia and systemic symptoms and stevens-johnson syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10090118" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Incidence of beta-lactam-induced delayed hypersensitivity and neutropenia during treatment of infective endocarditis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32044449" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Evaluating drug fever to beta-lactam antibiotics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23475582" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Intentional rechallenge and the clinical management of drug-related problems.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31400461" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Drug-induced severe cutaneous adverse reactions: Determine the cause and prevention.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22830618" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Drug Fever: a descriptive cohort study from the French national pharmacovigilance database.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
